Ashley H. Shoemaker, MD, MSCI
Dr. Shoemaker’s research focus is hypothalamic obesity, including genetic disorders and hypothalamic injury. By identifying the precise pathophysiology underlying different forms of syndromic obesity, Dr. Shoemaker is working to develop targeted weight loss treatments. Disorders studied include Prader-Willi syndrome, pseudohypoparathyroidism, MC4R pathway disorders, and adolescent type 2 diabetes.
Dr. Shoemaker has received funding from the National Institutes of Health, the Endocrine Fellow Foundation and the Doris Duke Foundation. She is a member of the EuroPHP Network Consensus Group on Pseudohypoparathyroidism. Her research has been published in the Journal of Clinical Endocrinology and Metabolism, International Journal of Obesity, Obesity, Nature Reviews Endocrinology and Hormone Research in Pediatrics. In 2012, she was named a Vanderbilt Scholar in Diabetes. In 2016, she received the Endocrine Society Early Investigator award.
Genetic obesity disorders; Prader-Willi syndrome; Pseudohypoparathyroidism; Type 2 diabetes; General endocrinology; diabetes
Specialty
Endocrinology, Pediatric
M.D.
Virginia Commonwealth University, Medical College of Virginia Campus, VA, 2006
Residency
Pediatric Residency-Johns Hopkins University, Baltimore, MD
Fellowship
Pediatric Endocrinology Fellowship-Vanderbilt University Medical Center, Nashville, TN
